Showing results (491-500 of 499) with videos related to

Sort By:
Pageof 50
You have reached the last page of results.This site can display upto 499 results.
The Journal of Clinical Endocrinology and Metabolism|November 25, 2011
Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulationG Johannsson, A G Nilsson, R Bergthorsdottir, et al.
American Journal of Human Genetics|April 16, 1998
Characterization of mutations in patients with multiple endocrine neoplasia type 1J H Bassett, S A Forbes, A A Pannett, et al.
The Journal of Clinical Endocrinology and Metabolism|November 24, 1999
Effect of severe growth hormone (GH) deficiency due to a mutation in the GH-releasing hormone receptor on insulin-like growth factors (IGFs), IGF-binding proteins, and ternary complex formation throughout lifeM H Aguiar-Oliveira, M S Gill, E S de A Barretto, et al.
British Journal of Cancer|August 13, 2009
The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stageS J Howell, C Searle, V Goode, et al.
Acta Chirurgica Belgica|February 27, 2010
The Immediate Management of the Patient with Rupture: Open Versus Endovascular repair (IMPROVE) aneurysm trial--ISRCTN 48334791 IMPROVE trialists, J T Powell, S G Thompson, et al.
American Journal of Human Genetics|October 3, 1998
Autosomal dominant nocturnal frontal-lobe epilepsy: genetic heterogeneity and evidence for a second locus at 15q24H A Phillips, I E Scheffer, K M Crossland, et al.
Endocrine-Related Cancer|February 12, 2009
Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumoursUmasuthan Srirangalingam, Bernard Khoo, Lisa Walker, et al.
ESMO Open|September 6, 2024
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 studyH S Rugo, M Oliveira, S J Howell, et al.
The New England Journal of Medicine|April 20, 2000
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomantP J Trainer, W M Drake, L Katznelson, et al.
Pageof 50